Pharmacopeia Scores Another Milestone (PCOP, GSK)

Health and Healthcare

Published: March 18, 2008 6:38 am

Pharmacopeia (Nasdaq: PCOP) has announced that it will receive a milestone payment of $5 million from GlaxoSmithKline (NYSE: GSK), bringing the total received to over $16 million in connection with its ongoing development and commercialization alliance.

The trigger for the additional milestone was Pharmacopeia’s completion of certain early discovery activities under its agreement with Glaxo. This alkso notes that Pharmacopeia is entitled to success-based milestone payments that can total up to $83 million per program for any drug development program pursued through the multi-program alliance. It can also receive up to double-digit royalties on the sales of any products commercialized by Glaxo under the alliance.

Before any pop here, Pharmacopeia had a mere $102 million market cap and had roughly $71.3 million in cash and equivalents on the books, and it also carried $67.3 million in total liabilities.

Jon C. Ogg
March 18, 2008

Smart Investors Are Quietly Loading Up on These “Dividend Legends”

If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.

Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.